Latest Conference Articles

Researchers hope that a more targeted retinoid acid X receptor compound could repair myelin without the adverse effects seen in every patient in this trial, which tested an already approved cancer drug.

Testing for coronavirus disease 2019 (COVID-19) before procedures has become a fixture of City of Hope's efforts to protect patients with cancer and staff, noted Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.

Aligned with ASCO's Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care.

Disease-modifying therapies (DMTs) are primarily effective through immunomodulation, in that they target relapse prevention, said Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

Progress within the adoption of clinical pathways, particularly in achieving standardization in cancer care, will be further discussed at Patient-Centered Oncology Care 2020®.

The uncertainties precipitated by the coronavirus disease 2019 (COVID-19) pandemic around cancer care delivery are a challenging topic to be further addressed at this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

Through this year's virtual format for Patient-Centered Oncology Care® 2020, participants will be able to attend sessions, ask questions, and gain insight in an immediate, efficient way.

The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

As cancer care providers, aligning care with each patient's personal goals is a key point to be further discussed at this year's Patient-Centered Oncology Care® 2020 virtual conference.

For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology.

At this year's Patient-Centered Oncology Care® 2020 virtual conference, purported lack of incentives, transparency in the supply chain of pharmacy benefit manager (PBM) operations, and the overall health care system will be discussed.

During a featured discussion at this year’s Patient-Centered Oncology Care® 2020 virtual meeting, innovations and subsequent challenges in employing these advances within the treatment of cancer will be addressed.

Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.

Nurses often get involved with patients with multiple sclerosis (MS) before their diagnosis and then work to educate them on the disease and its care, said Amy Perrin Ross, APN, MSN, CNRN, MSCN, Neuroscience Program Coordinator at Loyola University Medical Center.

To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

It is well known that women are disproportionately affected by multiple sclerosis (MS), but there remains a lack of understanding regarding gender differences in response to treatments for MS, said Riley Bove, MD, assistant professor of neurology at the UCSF Weill Institute for Neurosciences.

Do patients with multiple sclerosis who have been on disease-modifying therapies (DMTs) for decades need to keep taking them? John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine, and co-director of the Rocky Mountain MS Center at Anschutz Medical Campus, explains what is known about this area.

Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options.

Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.

The analysis, which was released on the first day of the meeting, was one of many that tried to demonstrate that earlier treatment in newly diagnosed and younger patients may forestall disease progression and disability.

Understanding each patient's individual story is vital in the transition to patient-centered care. Additionally, matching patients with physicians of the same race and background can boost comfortability among patients.

There is a push to diagnose multiple sclerosis (MS) earlier, which can lead to misdiagnosis if the diagnostic criteria aren’t used properly, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.

Providers need to focus on detecting and treating cardiovascular complications in at-risk patients, and not get lost in the fact they have COVID-19, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.

If you change the narrative and package SGLT-2 inhibitors as a form of cardiovascular risk modulation, cardiologists may be more likely to get involved in diabetes management, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

During the surge of the pandemic in the Northeast, we saw about a 40% reduction in cardiovascular admissions, while there was a higher rate of mortality among patients who came in, said Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School.

It is imperative individuals with cardiovascular diseases remain active despite COVID-19 lockdowns, said Antonio Pelliccia, MD, senior consultant and chief of cardiology at the Institute of Sports Medicine and Science, of the Italian National Olympic Committee.

Below are selected abstracts presented at the European Society of Cardiology 2020 Congress, which was held in a virtual format due to the coronavirus disease 2019 pandemic.